Short Interest in Bionano Genomics, Inc. (NASDAQ:BNGO) Grows By 11.4%

Bionano Genomics, Inc. (NASDAQ:BNGO) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 17,650,000 shares, an increase of 11.4% from the December 15th total of 15,840,000 shares. Based on an average trading volume of 6,670,000 shares, the short-interest ratio is currently 2.6 days. Currently, 12.7% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Carret Asset Management LLC boosted its stake in shares of Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after purchasing an additional 40,055 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Bionano Genomics during the third quarter valued at approximately $46,000. Geode Capital Management LLC boosted its position in Bionano Genomics by 47.3% during the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after acquiring an additional 283,639 shares during the last quarter. Finally, Armistice Capital LLC purchased a new stake in Bionano Genomics in the 2nd quarter worth approximately $1,138,000. Institutional investors and hedge funds own 11.35% of the company’s stock.

Bionano Genomics Price Performance

Shares of NASDAQ BNGO traded down $0.01 during trading on Friday, reaching $0.19. The company had a trading volume of 7,196,647 shares, compared to its average volume of 13,889,912. The company has a current ratio of 1.43, a quick ratio of 0.99 and a debt-to-equity ratio of 0.07. Bionano Genomics has a twelve month low of $0.18 and a twelve month high of $1.40. The stock has a 50-day moving average price of $0.24 and a two-hundred day moving average price of $0.38. The stock has a market capitalization of $22.61 million, a PE ratio of -0.08 and a beta of 2.22.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH lowered shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Friday, November 15th.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.